ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA
A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection to evaluate central nervous system (CNS) penetration.
A Phase 2 trial that studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to Bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient’s response to treatment.
RADIATION THERAPY PLANNING WITH FLUCICLOVINE PET FOR NEWLY DIAGNOSED GLIOBLASTOMA
A Phase 2 randomized trial studies the use of a PET scan with 18F-fluciclovine (Fluciclovine PET) in addition to the normal radiation planning imaging procedures (MRI and CT scan) will help determine the areas where the radiation therapy is to be delivered.
A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort.